Commercial carriers such as RNAiFectTM reagent (Qiagen), LipofectamineTM 2000 and OligofectamineTM(Invitrogen) were used to deliver CDC20, RAD51, and CHEK1 siRNA, respectively, and these studies were conducted in pancreatic, non-small-cell lung carcinoma (NSCLC), and osteosarcoma cell-lines. This evidence concerns the gene RAD51 and non-small cell lung carcinoma.